CEO Interview FY26 Results – Acrobat pdf 307k 18 August 2026 Interview with Dr Sam Hupert, CEO Pro Medicus Limited: Full-Year results AI-Visage-The Gateway Cardiology and new developments - Digital Pathology and Reporting Implementations and timing of revenue Cloud and other factors driving the industry Renewals and pipeline 4D Medical and EIQ Investments
18 August 2026; PME Full Year Results FY26 - Acrobat pdf 431k Highlights Reported Performance Revenue $261.7m - up 22.9% Underlying EBIT - $196.1m - up 24.4% NPAT $265.3m - up 130.3% Underlying NPAT $144.7m - up 24.1% Company remains debt-free with cash and other financial assets $252.3m - up 19.7% Fully-franked final dividend 37c per share, total dividend for year 69c - up 25.5% Constant Currency Performance Underlying Revenue on a constant currency $273.5m - up 28.4% Underlying EBIT on a constant currency $206m - up 30.6% Underlying Net profit after tax (NPAT) on a constant currency $154.5m - up 32.5% Operating Achievements 10 new contracts signed worth minimum A$407m Renewed 6 out of 6 contracts worth A$141m on 5-year terms EBIT margin 74.9% - up 90 basis points New product launches - digital pathology and AI-optimised reporting Trinity implementation largely complete, ready for full year contribution for FY27 Pro Medicus Limited (PME) has delivered a FY26 underlying NPAT of $144.7m, up +24.1% year-on-year. Revenue from ordinary activities was $261.7 million, up +22.9%. Reported NPAT of $265.3m, up +130.3%. Cash and other financial assets at the end of the period were $252.3 million, an increase of +19.7%. The company remains debt-free. Fully-franked final dividend of 37c per share, making total dividends for the year 69c, an increase of +25.5%. On a constant currency basis, excluding the impact of year-on-year currency movements, Pro Medicus' annual revenue was $273.5m, up +28.4%, underlying EBIT on constant currency was $206.0m, up +30.6%, and underlying NPAT on constant currency was $154.5 million, up 32.5%. Over the past five years, PME's revenue has increased 180%, equating to a compound annual growth rate (CAGR) of 29%. During the period, the company
CEO Interview HY26 results - Final – Acrobat pdf 115k 12 February 2026 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Half-Year results Sales and implementation update Investment in 4DX Impact of AI - disruptor or not Update on Cardiology and other "ologies" Pipeline
12 February 2026; Company Announcement - Pro Medicus Limited Interim Results - Acrobat pdf 150k Highlights Revenue from ordinary activities $124.8m – up 28.4% Underlying profit before tax $90.7m – up 29.7% Reported net profit after tax $171.2m – up 230.9% Underlying EBIT margins increase to 73% (HY25: 72%) Cash and other financial assets $221.8m – up 5.3% Company remains debt-free Fully franked interim dividend 32c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year underlying net profit of $67.3 million for the six months to the end of December 2025, 29.7% higher than for the previous corresponding period. Revenue from ordinary activities was $124.8 million, up 28.4%. Reported net profit after tax was $171.2 million, up 230.9%. This includes unrealised gains of $149.1 million before tax, from the company’s $10 million hybrid debt and equity investment in 4D Medical Limited in July 2025. Pro Medicus’ cash and other financial assets at December 2025 were $221.8 million, an increase of 5.3% despite paying out increased dividends, two share buybacks and the $10M investment in 4D Medical. The company announced a fully franked interim dividend of 32c per share. The company remains debt-free. During the period the company announced seven new contracts: A 10-year $A170 million contract with University of Colorado on 3 July 2025 (full stack and cardiology, go live May 2026) A 5-year $10 million contract with University Hospital Heidelberg on 8 October 2025 (Viewer and Archive, go live March 2026) A 5-year $A44 million contract with Advanced Radiology Management on 17 November 2025 (Viewer, go live second half 2026) A 5-year $A6.5 million contract with Children’s of Alabama on 24 November 2025 (full stack, implemented August
CEO Interview 2024-2025 Full-Year Results – Acrobat pdf 155k 14 August 2025 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Full-Year results Sales and implementation update Cloud and other factors driving the industry Update on Cardiology and other "ologies" Pipeline
14 August 2025; Company Announcement Full-Year Results 2024-25 - Acrobat pdf 364k Highlights Revenue from ordinary activities $213.0m – up 31.9% Underlying profit before tax $163.3m – up 40.2% Net profit $115.2m – up 39.2% Cash and other financial assets $210.7m – up 35.5% Company remains debt-free Record year for new contract wins, contract renewals and sale of additional modules to existing clients. Fully-franked final dividend 30c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full-year net profit of $115.2 million for the twelve months to the end of June 2025, 39.2% higher than the previous corresponding period. Revenue from ordinary activities was $ 213.0 million, up 31.9%. The company’s cash and other financial assets at the end of June 2025 were $210.7 million, an increase of 35.5%. Pro Medicus announced a fully-franked final dividend of 30c per share. The company remains debt-free. Revenue increased in all key jurisdictions: North America up 35.8%, Australia up 4.9% and Germany up 8.6%. During the year Pro Medicus announced $520 million in new contracts, including: A $330 million, ten-year contract with Trinity Health, one of the largest not-for-profit health care systems in the United States. A $30 million, 7-year contract with Duly Health and Care, the largest independent, multi-specialty physician-directed medical group in the USA Midwest. A $33 million, 9-year contract with University of Kentucky, the preeminent academic health system in Kentucky. A $5 million, 7-year contract with Lurie Children’s Hospital, a nationally ranked paediatric acute care children's hospital in Chicago. A $53 million, 7-year contract with BayCare, the leading health care system in the Tampa Bay and central Florida regions of the USA. A $40 million, 7-year contract with Lucid
FY25 Results Release Date – Acrobat pdf 204k 07 July 2025 Leading healthcare imaging company, Pro Medicus (ASX: PME), today announced its full year (FY25) results will be released on Thursday 14 August 2025. Pro Medicus will also host a webcast conference call on Thursday 14 August 2025 at 11.00am (AEST) - please refer to the link below: Webcast Public Link: https://ccmediaframe.com/?id=yGhMBXVe
CEO Interview Interim Results – Acrobat pdf 125k 13 February 2025 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: First half results Implementations and contract trends North American TAM and market segments Elucid, AI and other ologies Recent wins and pipeline
13 February 2025; Company Announcement - Half Year Results 2025 - Acrobat pdf 363k Highlights Revenue from ordinary activities $97.2m – up 31.1% Underlying profit before tax $69.9m – up 42.9% Net profit $51.7m – up 42.7% Underlying EBIT margins increase to 72% (HY24: 66%) Cash and other financial assets $182.3m – up 17.7% Company remains debt-free Fully franked interim dividend 25c per share Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a half-year net profit of $51.7 million for the six months to the end of December 2024, 42.7% higher than for the previous corresponding period. Revenue from ordinary activities was $97.2 million, up 31.1%. The result was driven largely by increased revenue from North America (revenue $86.4 million, up 34.6%). The company’s cash and other financial assets in December 2024 were $182.3 million, an increase of 17.7% in the six months. Pro Medicus announced a fully franked interim dividend of 25c per share. The company remains debt-free. During the period Pro Medicus won key contracts with Trinity Health, Lurie Children’s Hospital and Duly Health and Care. These contracts were for a combined minimum amount of $365 million spread over 7-10-year deals. In addition, the company renewed contracts with Mercy Health in the USA ($98 million, 8 years) and with a large Australian radiology practice ($32 million, 5 years). Additional modules were also added to existing contracts at both Duke Health (archive addition, $15 million, 5 years) and NYU Langone (archive addition, $24 million, 5 years). Pro Medicus CEO Dr Sam Hupert said he was very pleased with the result, which was a record one for the company in terms of both revenue and net profit, as well as new
CEO Interview - Full Year Results 2024 – Acrobat pdf 214k 14 August 2024 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Full-Year results Sales and implementation update Market segmentation and factors driving the industry Pipeline